CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH

临床试验：针对患有以下疾病的患者进行肽疫苗接种的 II 期试验

• 批准号: 8167154
• 负责人: Craig Lee Slingluff
• 金额: $ 0.8万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167154
• 关键词: CD4 Positive T Lymphocytes; CD8B1 gene; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Data; Epitopes; Funding; Grant; Helper-Inducer T-Lymphocyte; Immune response; Institution; MHC Class I Genes; Measurable; Multicenter Studies; Outcome; Patients; Peptide Vaccines; Peptides; Phase; Phenotype; Randomized; Research; Research Personnel; Resources; Secondary Immunization; Source; Staging; T cell response; T-Lymphocyte; United States National Institutes of Health; Vaccination; Vaccines; melanoma

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, multicenter study for patients with measurable, stage IV melanoma. This study will: (a) estimate whether the addition of helper peptides to class I MHC-restricted peptides augments T-cell responses to the Class I MHC-restricted peptides, (b) characterize the phenotype of vaccine-induced CD8+ T cells, (c) determine the helper T-cell response to each helper peptide, (d) obtain preliminary data on whether booster vaccination every three months may maintain immune responses to a peptide vaccine, and (e) obtain preliminary data on whether cellular immune responses to a 12-epitope peptide vaccine correlates with clinical outcome.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项针对可测量的 IV 期黑色素瘤患者的随机、多中心研究。 本研究将：(a) 估计向 I 类 MHC 限制性肽中添加辅助肽是否会增强 T 细胞对 I 类 MHC 限制性肽的反应，(b) 表征疫苗诱导的 CD8+ T 细胞的表型，( c) 确定辅助 T 细胞对每种辅助肽的反应，(d) 获得关于每三个月加强免疫是否可以维持对肽疫苗的免疫反应的初步数据，以及 (e) 获得关于细胞免疫是否可以维持免疫反应的初步数据对 12 表位肽疫苗的反应与临床结果相关。